Robert Tjin Tham Sjin

Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC

Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma et al. · Cancer Discovery · 2013 · 627 citations · Full text

Medicine, Oncology, Pharmacology +17

The novel primary response gene MyD118 and the proto-oncogenes myb, myc, and bcl-2 modulate transforming growth factor beta 1-induced apoptosis of myeloid leukemia cells.

Muthu Selvakumaran, Hsueh‐Kung Lin, Robert Tjin Tham Sjin et al. · Molecular and Cellular Biology · 1994 · 185 citations · Full text

Life Sciences, Cell Biology, Oncology +17

<i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing

Robert Tjin Tham Sjin, Kwangho Lee, Annette O. Walter et al. · Molecular Cancer Therapeutics · 2014 · 70 citations

Medicine, Oncology, Pharmacology +14

VRK1 Is a Synthetic–Lethal Target in VRK2-Deficient Glioblastoma

Julie A. Shields, Samuel R. Meier, Madhavi Bandi et al. · Cancer Research · 2022 · 65 citations · Full text

Life Sciences, Genetics, Oncology +17

Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts

Helen M. Nugent, Robert Tjin Tham Sjin, Desmond White et al. · Journal of Vascular Surgery · 2007 · 53 citations

Engineering, Bioengineering, Biomedical Engineering +16